Need Help?
No Article Versions Notes Found
Cite
Juergens, R.A.; Mariano, C.; Jolivet, J.; Finn, N.; Rothenstein, J.; Reaume, M.N.; Faghih, A.; Labbé, C.; Owen, S.; Shepherd, F.A.; et al. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Curr. Oncol. 2018, 25, 384-392. https://doi.org/10.3747/co.25.4287
Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, Faghih A, Labbé C, Owen S, Shepherd FA, et al. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology. 2018; 25(6):384-392. https://doi.org/10.3747/co.25.4287
Chicago/Turabian StyleJuergens, R.A., C. Mariano, J. Jolivet, N. Finn, J. Rothenstein, M.N. Reaume, A. Faghih, C. Labbé, S. Owen, F.A. Shepherd, and et al. 2018. "Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort" Current Oncology 25, no. 6: 384-392. https://doi.org/10.3747/co.25.4287
APA StyleJuergens, R. A., Mariano, C., Jolivet, J., Finn, N., Rothenstein, J., Reaume, M. N., Faghih, A., Labbé, C., Owen, S., Shepherd, F. A., Villeneuve, J., Romeyer, F., Pettersson, F., & Butts, C. (2018). Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology, 25(6), 384-392. https://doi.org/10.3747/co.25.4287
